|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005961,
umls-concept:C0019728,
umls-concept:C0025677,
umls-concept:C0030705,
umls-concept:C0085149,
umls-concept:C0199176,
umls-concept:C0282460,
umls-concept:C0445356,
umls-concept:C0856825,
umls-concept:C1333899,
umls-concept:C1556094,
umls-concept:C1837204
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2009-1-14
|
|
pubmed:abstractText |
Bone marrow transplantation from unrelated donors (UR-BMT) has been considered to be effective for patients with hematological malignancies who have no suitable related donor. However, disparities of HLA between a recipient and a donor increase the risk of severe acute graft-versus-host disease (GVHD). We evaluated GVHD prophylaxis using tacrolimus and methotrexate for HLA-A, B, or DRB1 genotypically mismatched UR-BMT. Fifty-five patients were enrolled in this study. The incidence of grade III to IV acute GVHD was 23.6% for all patients. No significant difference in the incidence of grade III to IV acute GVHD was observed between HLA-A or B 1 locus mismatch transplantation (18.8%) and HLA-DRB1 1 locus mismatch transplantation (16.7%) (P = 0.96). The incidence of chronic GVHD was 71.7%. Disease-free survival at 5 years was 53.2% for patients with standard risk disease and 24.5% for patients with high-risk disease. Patients with chronic GVHD exhibited better disease-free survival than those without chronic GVHD (53.2 vs. 30.9%, P = 0.011). Twenty patients (36.4%) had a relapse of leukemia and 14 of them died of recurrent leukemia. This study indicates tacrolimus and methotrexate can lower the risk of severe acute GVHD after HLA-A, B, or DRB1 genotypically 1 locus mismatched UR-BMT.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1865-3774
|
|
pubmed:author |
pubmed-author:AtsutaYoshikoY,
pubmed-author:HaraMasamichiM,
pubmed-author:HiraiHisamaruH,
pubmed-author:KanamoriHeiwaH,
pubmed-author:KoderaYoshihisaY,
pubmed-author:MatsuoKeitaroK,
pubmed-author:MorishimaYasuoY,
pubmed-author:MurayamaTohruT,
pubmed-author:NishidaTetsuyaT,
pubmed-author:OkamotoShinichiroS,
pubmed-author:SaoHiroshiH
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
89
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
98-105
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19052693-Acute Disease,
pubmed-meshheading:19052693-Adolescent,
pubmed-meshheading:19052693-Adult,
pubmed-meshheading:19052693-Asian Continental Ancestry Group,
pubmed-meshheading:19052693-Bone Marrow Transplantation,
pubmed-meshheading:19052693-Cause of Death,
pubmed-meshheading:19052693-Female,
pubmed-meshheading:19052693-Graft vs Host Disease,
pubmed-meshheading:19052693-HLA Antigens,
pubmed-meshheading:19052693-HLA-A Antigens,
pubmed-meshheading:19052693-HLA-B Antigens,
pubmed-meshheading:19052693-HLA-DR Antigens,
pubmed-meshheading:19052693-HLA-DRB1 Chains,
pubmed-meshheading:19052693-Histocompatibility Testing,
pubmed-meshheading:19052693-Humans,
pubmed-meshheading:19052693-Male,
pubmed-meshheading:19052693-Methotrexate,
pubmed-meshheading:19052693-Middle Aged,
pubmed-meshheading:19052693-Tacrolimus,
pubmed-meshheading:19052693-Treatment Outcome,
pubmed-meshheading:19052693-Young Adult
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Phase II study of tacrolimus and methotrexate for prophylaxis of acute graft-versus-host disease after HLA-A, B, and DRB1 genotypically mismatched unrelated bone marrow transplantation among Japanese patients.
|
|
pubmed:affiliation |
Department of Internal Medicine, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan. tnishida@med.nagoya-u.ac.jp
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
